150 related articles for article (PubMed ID: 38888917)
21. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
22. A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.
Ghoreishi Amin N; Khosravi S; Atefi N; Seirafianpour F; Farhoodi S; Goodarzi A
Immun Inflamm Dis; 2023 Nov; 11(11):e1063. PubMed ID: 38018599
[TBL] [Abstract][Full Text] [Related]
23. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Huang IH; Wu PC; Chiu HY; Huang YH
Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
[TBL] [Abstract][Full Text] [Related]
24. Anti-TNF agents for paediatric psoriasis.
Sanclemente G; Murphy R; Contreras J; García H; Bonfill Cosp X
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010017. PubMed ID: 26598969
[TBL] [Abstract][Full Text] [Related]
25. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
Jairath V; Zou GY; Parker CE; MacDonald JK; AlAmeel T; Al Beshir M; Almadi MA; Al-Taweel T; Atkinson NS; Biswas S; Chapman T; Dulai PS; Glaire MA; Hoekman DR; Koutsoumpas A; Minas E; Mosli MH; Samaan M; Khanna R; Travis S; D'Haens G; Sandborn WJ; Feagan BG
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011572. PubMed ID: 28886205
[TBL] [Abstract][Full Text] [Related]
26. Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW; Warren RB; Zhong Y; Zhuo J; Cichewicz A; Kadambi A; Junqueira D; Westley T; Kisa R; Daamen C; Augustin M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2839-2857. PubMed ID: 37801281
[TBL] [Abstract][Full Text] [Related]
27. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
30. Deployment of personnel to military operations: impact on mental health and social functioning.
Bøg M; Filges T; Jørgensen AMK
Campbell Syst Rev; 2018; 14(1):1-127. PubMed ID: 37131363
[TBL] [Abstract][Full Text] [Related]
31. Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease: A Systematic Review and Meta-analysis.
Chen TL; Lee LL; Huang HK; Wang JH; Chen LY; Tsai HR; Loh CH; Chi CC
JAMA Dermatol; 2022 Jan; 158(1):59-67. PubMed ID: 34851364
[TBL] [Abstract][Full Text] [Related]
32. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
[TBL] [Abstract][Full Text] [Related]
35. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions.
Page MJ; McKenzie JE; Kirkham J; Dwan K; Kramer S; Green S; Forbes A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):MR000035. PubMed ID: 25271098
[TBL] [Abstract][Full Text] [Related]
36. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
[TBL] [Abstract][Full Text] [Related]
37. Impact of residual skin lesions and previous biologic treatment failure on patient-reported outcomes in patients with psoriasis receiving biologic treatment.
Song WJ; Yoon HS
J Dermatol; 2024 Jun; 51(6):772-778. PubMed ID: 38660957
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]